Mutations of epigenetic genes and correlation with treatment response in peripheral T-cell lymphoma

Chong Wei; Wei Wang; Wanying Li; Yan Zhang; Danqing Zhao; Wei Zhang; Daobin Zhou

doi:10.1002/ctm2.1491

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (1) : e1491 DOI: 10.1002/ctm2.1491

LETTER TO THE JOURNAL

Mutations of epigenetic genes and correlation with treatment response in peripheral T-cell lymphoma

Author information +

History +

PDF

Cite this article

Download citation ▾

Chong Wei, Wei Wang, Wanying Li, Yan Zhang, Danqing Zhao, Wei Zhang, Daobin Zhou. Mutations of epigenetic genes and correlation with treatment response in peripheral T-cell lymphoma. Clinical and Translational Medicine, 2024, 14(1): e1491 DOI:10.1002/ctm2.1491

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748.

[2]	Liu W, Ji X, Song Y, et al. Improving survival of 3760 patients with lymphoma: experience of an academic center over two decades. Cancer Med. 2020.

[3]	Armitage JO. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol. 2017;92(7):706-715. PMID:28516671

[4]	Lemonnier F, Couronne L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120(7):1466-1469.

[5]	Dobay MP, Lemonnier F, Missiaglia E, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017;102(4):e148-e151.

[6]	Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827-5834.

[7]	Ruan J, Moskowitz A, Mehta-Shah N, et al. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023;141(18):2194-2205.

[8]	Zhang W, Su L, Liu L, et al. The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study. Cancer Biol Med. 2021;18(3):841-848.

[9]	Chong W, Yan Z, Jian L, et al. A multicenter, phase III study of chidamide, azacitidine combined with CHOP versus CHOP in patients with untreated peripheral T-Cell lymphoma. Blood. 2022;140(1):6567-6568.

[10]	Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161-2170.

[11]	Ji MM, Huang YH, Huang JY, et al. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. Haematologica. 2018;103(4):679-687.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.